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Cardiospecific Overexpression of ATPGD1
(Carnosine Synthase) Increases Histidine
Dipeptide Levels and Prevents Myocardial
Ischemia Reperfusion Injury
Jingjing Zhao, PhD; Daniel J. Conklin, PhD; Yiru Guo, PhD; Xiang Zhang, PhD; Detlef Obal, MD, PhD;
Luping Guo, MD; Ganapathy Jagatheesan, PhD; Kartik Katragadda, MD; Liqing He, PhD; Xinmin Yin, MS;
Md Aminul Islam Prodhan, PhD; Jasmit Shah, PhD; David Hoetker, MS; Amit Kumar, PhD; Vijay Kumar, PhD;
Michael F. Wempe, PhD; Aruni Bhatnagar, PhD; Shahid P. Baba, PhD
BACKGROUND: Myocardial ischemia reperfusion (I/R) injury is associated with complex pathophysiological changes characterized by pH imbalance, the accumulation of lipid peroxidation products acrolein and 4-hydroxy trans-2-nonenal, and the
depletion of ATP levels. Cardioprotective interventions, designed to address individual mediators of I/R injury, have shown
limited efficacy. The recently identified enzyme ATPGD1 (Carnosine Synthase), which synthesizes histidyl dipeptides such
as carnosine, has the potential to counteract multiple effectors of I/R injury by buffering intracellular pH and quenching lipid
peroxidation products and may protect against I/R injury.
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METHODS AND RESULTS: We report here that β-alanine and carnosine feeding enhanced myocardial carnosine levels and protected the heart against I/R injury. Cardiospecific overexpression of ATPGD1 increased myocardial histidyl dipeptides levels
and protected the heart from I/R injury. Isolated cardiac myocytes from ATPGD1-transgenic hearts were protected against
hypoxia reoxygenation injury. The overexpression of ATPGD1 prevented the accumulation of acrolein and 4-hydroxy trans-2-
nonenal–protein adducts in ischemic hearts and delayed acrolein or 4-hydroxy trans-2-nonenal–induced hypercontracture in
isolated cardiac myocytes. Changes in the levels of ATP, high-energy phosphates, intracellular pH, and glycolysis during low-
flow ischemia in the wild-type mice hearts were attenuated in the ATPGD1-transgenic hearts. Two natural dipeptide analogs
(anserine and balenine) that can either quench aldehydes or buffer intracellular pH, but not both, failed to protect against I/R
injury.
CONCLUSIONS: Either exogenous administration or enhanced endogenous formation of histidyl dipeptides prevents I/R injury by
attenuating changes in intracellular pH and preventing the accumulation of lipid peroxidation derived aldehydes.
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M

yocardial ischemia leads to a complex series
of pathological changes that involve multiple
deleterious events such as a switch to anaerobic glucose metabolism and intracellular acidification and increased generation of reactive oxygen
species (ROS), which initiate the formation of toxic

lipid peroxidation products. If uninterrupted, these
changes lead to extensive tissue injury and sustained
contractile dysfunction. Therefore, the most effective
intervention to rescue ischemic myocardium is timely
reperfusion using thrombolytic therapy or by percutaneous coronary intervention. However, reperfusion by
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CLINICAL PERSPECTIVE
What Is New?

• This research demonstrates that enhancing
myocardial production of histidyl dipeptides
by cardiospecific carnosine synthase overexpression or feeding carnosine and β-alanine
imparts protection from ischemia reperfusion
injury.
• Decrease in intracellular pH and the accumulation of reactive aldehydes are 2 deleterious
characteristics of ischemia reperfusion injury.
• Histidyl dipeptides by their dual ability to buffer
intracellular pH and scavenging reactive aldehydes impart protection from ischemia reperfusion injury.

What Are the Clinical Implications?

• Histidyl dipeptides are food components found
in red meat that are increased by exercise.
• Therefore, our findings lay the foundation to test
the translational feasibility of these dipeptides
as a prophylactic measure to prevent ischemic
heart diseases.

Nonstandard Abbreviations and Acronyms
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AAR
ATPGD1
I/R
LFI
ROS

area at risk
carnosine synthase
ischemia reperfusion
low-flow ischemia
reactive oxygen species

itself initiates a second cascade of complex pathological events, collectively defined as “reperfusion injury,”
characterized by rapid restoration of intracellular pH
([pH]i), release of cardiac enzymes, mitochondrial permeability transition pore opening, and eventually cell
death.1 In the past, most therapeutic interventions to
limit ischemia reperfusion (I/R) injury were designed to
target a single effector (eg, antioxidants, pH buffers,
or metabolic substrates),which showed only limited efficacy because preventing one aspect of I/R did not
necessarily attenuate injury attributed to other contributing processes.
Multifunctional histidyl dipeptides, such as carnosine (β-
alanine-
histidine), have been evolutionarily conserved for at least 530 million years and
are present in the muscles of families as distantly
related as fish, amphibians, birds, and mammals.2
Although the specific roles of these peptides in muscle physiology is still unclear, it is thought that by
the virtue of their dissociation constant (pKa) value,

which is close to physiological pH (7.01), some of
these peptides may buffer [pH]i.3 This property
may be particularly useful under conditions of hypoxia, when high amounts of protons are generated by anaerobic glycolysis. However, in addition
to buffering, these peptides can also quench ROS
as well as reactive aldehydes such as acrolein,
and 4-hydroxy-trans-2-nonenal (HNE),4–6 produced
during the oxidation of membrane lipids. It has also
been proposed that histidyl dipeptides act as a
neuromodulators or a neurotransmitters.7 In most
vertebrates, histidyl dipeptides are present in high
concentrations in skeletal muscle (1–10 mmol/L) and
heart (0.1–1 mmol/L) tissues,2 in which they are locally synthesized by the enzyme ATPGD1 (carnosine
synthase) from their precursors β-alanine and histidine.8 Although the chemical properties of histidyl
dipeptides are well suited to limit the effects of tissue
hypoxia and I/R injury, it is unclear whether increasing the endogenous synthesis of these peptides by
ATPGD1 overexpression protects against tissue injury and whether the complex I/R pathophysiology
is affected by augmenting histidyl dipeptide levels.
During myocardial ischemia, the most prompt
and marked change that occurs within the seconds
after the onset of ischemia is cellular acidosis.9,10
This decrease in [pH]i causes a rapid breakdown of
high-energy phosphates, increases inorganic phosphates, and downregulates contraction near the
ischemic zone.9,11 In response to ischemic acidosis, H+ ions are extruded by the Na+-H+ exchanger
to normalize [pH]i during reperfusion, but this results
in intracellular accumulation of Na+, which in turn is
exchanged for Ca 2+ overload and the opening of the
mitochondrial permeability pore.12,13 Several Na+-H+
exchanger inhibitors in animal models had either
resulted in modest recovery or had significant detrimental effects on I/R injury, but the clinical trials
involving Na+-H+ exchanger inhibitors were largely
negative.14,15 In addition to acidosis, I/R generates
toxic lipid peroxidation products, which accumulate
in the heart even after reperfusion.16,17 These products, particularly HNE and acrolein, can lead to coronary vasodilation18 and decrease systolic pressure19
and arrhythmias.20,21 They can also deplete ATP levels, alter Na+ and K+ conductances, and induce cell
death.20 The contribution of these aldehydes to I/R
injury is supported by extensive evidence showing
that the deletion of enzymes that detoxify these aldehydes, including glutathione-
S-transferase P,22
23,24
aldose reductase,
and aldehyde dehydrogenase
2, increases I/R injury.25,26 Therefore, a combinatorial
strategy that could reduce acidification and prevent
the accumulation of reactive aldehydes might be well
suited to ameliorate concurrently several adverse
factors of I/R injury.
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Previous work from our laboratory and others
have shown that the perfusion of isolated murine
hearts by carnosine offers modest protection against
I/R injury,27,28 and intravenous injection of carnosine
in rats imparts cerebroprotection.29 Nevertheless,
from these studies it is not clear whether these dipeptides act at intracellular sites or if these effects
are systemic. Importantly, it is not known whether the
cardioprotective effects of carnosine are related to
pH buffering and/or aldehyde quenching and how it
affects glucose use in the heart. In addition, in humans, histidyl dipeptides are rapidly hydrolyzed by
the carnosine-specific peptidase carnosinase present in the serum, which limits its bioavailability.30
Recent clinical trials in heart failure patients showed
that carnosine feeding did not improve cardiac function, reflecting a limitation to carnosine ingestion in
this setting.31 Hence, we increased the myocardial
histidyl dipeptide pool by the cardiospecific overexpression of ATPGD1. Our results showed that
ATPGD1 overexpression enhances the myocardial
pool of histidyl dipeptides and diminished myocardial infarct size. The results of mechanistic studies
showed that both aldehyde quenching and [pH]i buffering are essential actions for optimal cardio protection by histidyl dipeptides.
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METHODS
Adult male C57BL/6 mice were obtained from The
Jackson Laboratory (Bar Harbor, ME). All animal protocols were reviewed and approved by the University of
Louisville Institutional Animal Use and Care Committee.
Detailed methodology is described in Data S1.
ATPGD1-transgenic (Tg) mice were generated using
the α–myosin heavy chain promoter and subjected
to in vivo coronary ligation and reperfusion to induce
I/R injury. Nuclear magnetic resonance (NMR) was
used to quantify changes in pH in isolated perfused
hearts, and metabolites were measured by liquid chromatography–mass spectrometry or gas chromatography–tandem mass spectrometry (see Data S1, and
raw data will be provided on request). All of the data
and methods used in the analysis and material used
to conduct research will be made available at request.

Statistical Analysis
The levels of carnosine and infarct size in carnosine and
β-alanine–treated and untreated mice hearts, infarct
size of C57BL/6, wild type littermates (WT mice) and
ATPGD1-Tg mice hearts subjected to in vivo ischemia
reperfusion, and postischemic functional recovery following global ischemia in WT and ATPGD1-Tg–isolated
mice hearts were analyzed by using unpaired t test.
High-energy phosphates measured by 31P NMR and

Carnosine Protects From Ischemia Reperfusion

13

C lactate formation generated during low-
flow ischemia (LFI) and reperfusion in WT and ATPGD1-Tg
mice hearts were analyzed using repeated analysis
of variance. Synthesis of carnosine in hearts isolated
from WT and ATPGD1-Tg mice were analyzed by using
the Mann-
Whitney nonparametric test. Cytotoxicity
of isolated cardiomyocytes isolated from WT and
ATPGD1-Tg mice hearts that were subjected to normoxia and hypoxia/reperfusion and generation of aldehyde protein adducts after ischemia in the WT and
ATPGD1-Tg mice hearts were analyzed by using 2-way
analysis of variance followed by bonferroni test. To
estimate the survival time of isolated cardiomyocytes
between different treatments, 4 different models of estimating survival were evaluated as mentioned previously.32 Fits of exponential, Weibull, linear exponential,
and γ distribution to the data were estimated using a
regression method for survival distribution fitting.33 The
best fits were obtained for the Weibull distribution. This
distribution has been used to determine the survival
in continuous carcinogenesis and isolated cardiomyocytes.22,32,34 Survival data for cardiac myocytes were
modeled using the Weibull survival distribution. Curve
fitting was performed using the Proc NLIN procedure
in SAS version 9.4 software (SAS Institute, Inc., Cary,
NC). Two Weibull distributions were compared as described previously.35 The number of observations “n”
refers to the number of different mice hearts, and ~100
cells were counted from each mouse heart. Statistical
significance was accepted at P<0.05. Group data are
mean±SD and mean±SEM.

RESULTS
Carnosine and β-Alanine Feeding Protect
the Heart From I/R Injury
To increase intracellular levels of carnosine, we
placed adult male C57BL/6 mice on drinking water
containing β-alanine (20 mg/mL). β-
alanine is the
nonproteinogenic rate-
limiting amino acid that is
used for carnosine synthesis. It is widely used as
a food supplement to increase carnosine levels in
skeletal muscle.36,37 As shown in Figure 1A, after
7 days on β-alanine–containing water, carnosine levels were ≈7-fold higher in the hearts of treated than
untreated mice (0.31±0.05 nmoles/mg protein versus
2.26±0.08 nmoles/mg protein). There was no change
in anserine levels (0.0754±0.008 nmoles/mg protein
versus 0.068±0.001 nmoles/mg protein; Figure S1E).
To evaluate the effect of elevated myocardial carnosine levels, these mice were subjected to coronary
ligation for 30 minutes followed by 24 hours of reperfusion. Heart tissues were perfused with Evans
blue dye and stained with 2,3,5-
triphenyl tetrazolium chloride to characterize the area at risk (AAR)
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Figure 1. β-alanine and carnosine feeding protect against ischemia reperfusion injury.
A. Wild-type C57BL/6 mice were provided drinking water without (n=4) or with β-alanine (20 mg/mL; n=3) for 7 days. Myocardial
carnosine levels were measured by ultra-performance liquid chromatography/tandem mass spectrometry. Inset is a representative
chromatogram of carnosine and internal standard (IS) tyrosine histidine. B, Hearts of untreated and β-alanine–fed mice subjected
to 30 minutes of ischemia followed by 24 hours of reperfusion. Representative cross-sections of 2,3,5 triphenyltetrazolium chloride
staining shows the infarct zone depicted by a white area, the red area is the area at risk (AAR), and the blue region is the remote
zone. (Scale bar=1 mm.) C and D, The relative ratios of the AAR to the left ventricle (LV) area and the infarct area (IF) to the AAR
were compared between the untreated (n=8) and β-alanine–fed (n=9) fed mice. E, Mice provided drinking water with or without
carnosine (10 mg/mL) for 7 days; n=3 mice in each group. F, Representative cross-sections of the untreated and carnosine-treated
mice subjected to 30 minutes of ischemia followed by 24 hours of reperfusion. G and H, Relative ratio of AAR to the LV area and IF to
the AAR were compared between the untreated (n=9) and carnosine-treated mice groups (n=11). *P<0.05 vs the untreated mice group.

and infarct size. Figure 1B shows the representative
2,3,5-triphenyl tetrazolium chloride micrographs of
the heart tissues. Quantitative analysis of Evans blue
dye and 2,3,5-
triphenyl tetrazolium chloride staining, indicated that the AAR/left ventricle ratio was
similar between the untreated and β-alanine–treated
mice (Figure 1C). However, the infarct area as a
ratio of AAR was significantly lower in the β-alanine–
treated than in the untreated mice (Figure 1D). To
examine whether carnosine itself was as effective
as its precursor, we placed the WT mice on drinking water ±10 mg/mL carnosine for 7 days, which
led to a 5-fold increase in myocardial carnosine levels (0.15±0.04 nmoles/mg protein versus 0.71±0.19
nmoles/mg protein; Figure 1E). Again, there was no
change in anserine levels (Figure S1F). Similar to β-
alanine, carnosine feeding protected the heart from
I/R damage, as reflected by a lower infarct area/AAR
ratio in the hearts of the carnosine-fed mice subjected to coronary ligation and perfusion (Figure 1H).
Taken together, these results suggest that increasing

myocardial levels of carnosine via the delivery of carnosine or its precursor has an infarct-sparing effect.
In addition, these findings strengthened the rationale for testing the role of ATPGD1, which synthesizes
these dipeptides.8

Cardiospecific Overexpression of ATPGD1
Protects Against I/R Injury
The enzyme ATPGD1 ligates β-alanine and histidine to
form carnosine, which could be further methylated by
carnosine N-methyltransferase to form anserine.2,8,38 To
examine whether the cardiospecific ATPGD1 overexpression increases myocardial levels of histidyl dipeptides,
we generated the Tg mice overexpressing the mouse
ATPGD1 gene under the control of α–myosin heavy chain
promoter on a C57/BL6 background. Western blot analysis confirmed that the ATPGD1 expression in the heart was
increased ≈20-to 25-fold compared with the littermate
non-Tg control (WT) mice (Figure 2A). Liquid chromatography–mass spectrometry measurements showed that
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Figure 2. Cardiospecific overexpression of ATPGD1 (carnosine synthase) increases histidyl
dipeptide levels and protects against ischemia reperfusion injury.
A, Representative Western blot of ATPGD1 in wild-t ype (WT) and ATPGD1-transgenic (Tg) hearts (i); lower
panel represents the band intensity normalized to tubulin between the 2 groups (ii); n=4 in each group.
B, Fold changes in carnosine and anserine levels in WT and ATPGD1-Tg hearts, n=4 in each group. C,
Representative images of 2,3,5-triphenyl tetrazolium chloride–stained WT and ATPGD1-Tg hearts after
30 minutes of ischemia followed by 24 hours of reperfusion. D and E, Quantification of the ratio of area of
risk (AAR) and left ventricle (LV) and the ratio of infarct size (IF) and AAR in the WT (n=6) and ATPGD1-Tg
(n=7) hearts. Results are mean±SEM. *P<0.05 vs WT mice hearts.

the carnosine and anserine levels were increased 30-to
40-fold and 10-to 12-fold, respectively, in the ATPGD1-Tg
compared with the WT hearts (carnosine, WT: 0.31±0.04
nmoles/mg protein versus ATPGD1Tg: 14.57±0.39
nmoles/mg protein; anserine, WT: 0.075±0.008 nmoles/

mg protein versus ATPGD1Tg: 0.791±0.137 nmoles/mg
protein; Figure 2B, Figure S1A and S1B). The levels of
both of these dipeptides in gastrocnemius skeletal muscle remained unchanged, attesting to the fidelity of the
α–myosin heavy chain promoter (Figure S1C and S1D).
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Figure 3. ATPGD1 (carnosine synthase) overexpression prevents contractile dysfunction and
cardiomyocytes death.
A, Changes in the developed pressure of hearts isolated from the wild-t ype (WT) and ATPGD1-transgenic
(Tg) mice during 10 to 12 minutes of perfusion followed by 30 minutes of ischemia and 45 minutes of
reperfusion. Data are mean±SEM, n=4 mice hearts in each group; *P<0.05 vs WT heart. B and C, Levels
of lactate dehydrogenase (LDH) and creatine kinase (CK) released in the perfusate collected at different
intervals of reperfusion. D, LDH release in the WT and ATPGD1-Tg isolated cardiomyocytes under normoxia
and hypoxia/reoxygenation (H/R) conditions. Results are mean±SEM, n=6 in each group. *P<0.05 vs
WT normoxia, #P<0.05 vs ATPGD1-Tg normoxia, and ^P<0.05 vs WT H/R-treated cardiomyocytes. LVDP
indicates left ventricular developed pressures.

Echocardiographic analysis showed that at baseline morphometric data and function were similar between the
ATPGD1-Tg and WT mice hearts (Table S1). To determine
the effect of ATPGD1 overexpression on I/R injury, we
subjected the WT and ATPGD1-Tg mice hearts to coronary ligation and reperfusion. Quantitative analysis of the
2,3,5-triphenyl tetrazolium chloride staining showed that
the AAR was similar between the WT and ATPGD1-Tg
mice hearts; however, the infarct size decreased significantly by ATPGD1 overexpression (Figure 2C through 2E).
Taken together, these findings suggest that increasing the

endogenous production of histidyl dipeptides within the
heart protects from I/R injury.

ATPGD1 Overexpression Improves
Postischemic Function and Protects
Myocytes From Hypoxia Reoxygenation
Injury
Although our results showed that carnosine protects against I/R in vivo, this could be attributed to
direct effects of the dipeptide in cardiomyocytes or
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Figure 4. ATPGD1 (carnosine synthase) attenuates aldehyde accumulation and toxicity.
Representative Western blots of the wild-t ype (WT) and ATPGD1-transgenic (Tg) mice hearts after 30 minutes of sham and coronary
ligations. The anterior zone (AZ) from sham-operated and the ischemic zone (IZ) from coronary-ligated mice hearts were developed
with (A) anti–4-hydroxy-trans-2-nonenal (HNE) and (D) anti-acrolein antibodies and normalized with Amido-black (AB). Relative
band intensities of HNE (B and C) and acrolein-modified (E and F) protein bands. Data are mean±SEM. ^P<0.05 vs WT sham AZ,
*P<0.05 vs ATPGD1-Tg AZ, #P<0.05 vs WT IZ; n=4 in each group. G, Representative images of adult cardiomyocytes isolated from
the WT and ATPGD1-Tg hearts at 0 and 60 minutes of superfusion with HNE (50–60 μmol/L). (Scale bar=100 μmol/L.) H, Survival
plots of cardiomyocytes isolated from WT (n=7) and ATPGD1-Tg (n=5) hearts superfused with HNE, 100 cells from each heart.
Data are shown as discrete points, and the curves are best fits of a Weibull survival function. I, Graph showing the mean lifetime
of WT and ATPGD1-Tg cardiomyocytes in the presence of HNE are presented as mean±SEM. *P<0.05 vs WT HNE superfused
cardiomyocytes. J, Representative images of myocytes isolated from WT and ATPGD1-Tg hearts at 0 and 60 minutes of superfusion
with acrolein (5 μmol/L). (Scale bar=100 μmol/L.) K, Survival plots of cardiomyocytes isolated from WT (n=7) and ATPGD1-Tg (n=6)
hearts superfused with HNE, 100 cells from each heart. Data are shown as discrete points and the curves are best fits of the
Weibull survival function. L, Graph showing the mean lifetime of WT and ATPGD-Tg cardiomyocytes. *P<0.05 vs WT acrolein-treated
myocytes.

J Am Heart Assoc. 2020;9:e015222. DOI: 10.1161/JAHA.119.0152227

Zhao et al

Downloaded from http://ahajournals.org by on January 10, 2021

neurohormonal and inflammatory responses triggered
by coronary occlusion and reperfusion. Hence, to exclude neurohormonal and inflammatory responses, we
perfused isolated WT and ATPGD1-Tg mice hearts in
the Langendorff mode for 10 to 12 minutes and then
subjected them to 30 minutes of global ischemia followed by 45 minutes of reperfusion. At baseline, the
left ventricular developed pressures were comparable
between the WT and ATPGD1-Tg hearts; however, during reperfusion, the ATPGD1-Tg hearts had improved
systolic functional recovery, as demonstrated by higher
left ventricular developed pressures compared with the
WT mice hearts (Figure 3A). Similarly, the release of the
myocardial enzymes lactate dehydrogenase and creatine kinase was less in the ATPGD1-Tg than in the WT
hearts, indicating the cardiospecific protection attributed to ATPGD1 overexpression (Figure 3B and 3C).
To localize further the site of action of ATPGD1, we
isolated the cardiac myocytes from the WT and
ATPGD1-
Tg mice hearts and subjected them to either normoxia (5 hours) or hypoxia (3 hours) followed
by 2 hours of reoxygenation. The WT cardiac myocytes subjected to hypoxia and reoxygenation showed
greater lactate dehydrogenase release than normoxic
cardiac myocytes; however, the lactate dehydrogenase release in myocytes from the ATPGD1-Tg hearts
subjected to hypoxia and reoxygenation was similar to
that from normoxic WT cells, and significantly lower
than the WT myocytes subjected to hypoxia and reoxygenation (Figure 3D). Collectively, these data indicate
that increased intracellular levels of carnosine protect
myocytes from the deleterious effects of hypoxia and
reoxygenation.

ATPGD1 Overexpression Prevents
Aldehyde Accumulation in Ischemic
Hearts and Protects Aldehyde Toxicity
Given our findings that ATPGD1-Tg mice hearts are
protected from I/R injury, we next determined the
mechanism by which ATPGD1 overexpression affects
the heart during ischemia. For this, we subjected the
WT and ATPGD1-Tg mice hearts to 40 minutes of coronary ligation in vivo and analyzed the ischemic zone
of the ligated hearts and the anterior zone of the sham-
operated hearts for protein-HNE and protein-acrolein
adducts by Western blotting. Our results showed that
the protein-HNE adducts were more abundant in the
ischemic zone of the WT ischemic hearts than in the
anterior zone of the sham-operated WT and ATPGD1
hearts. Importantly, the accumulation of the protein-
HNE adducts was mitigated in the ischemic zone of
the ATPGD1-Tg mice hearts (Figure 4A through 4C).
Moreover, less protein-
acrolein adducts accumulated in the ischemic zone of ATPGD1-
Tg ischemic
hearts (Figure 4D through 4F). These observations are
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consistent with the notion that elevated levels of carnosine decreases the accumulation of lipid peroxidation–
derived aldehydes in the ischemic hearts.
Given that aldehyde protein-adduct accumulation was
diminished in the ATPGD1-
Tg ischemic hearts, we
next tested whether ATPGD1 overexpression would
protect against aldehyde toxicity. Previous work has
shown that these aldehydes induce myocyte hypercontracture.20,21 Therefore, we perfused myocytes isolated from the WT and ATPGD1-Tg hearts with HNE
for 60 minutes, continuously monitored their shape
under a light microscope, and calculated cell survival
using the Weibull distribution function. These analyses showed that although HNE perfusion caused hypercontracture in both WT and ATPGD1-
Tg cardiac
myocytes, the mean lifetime of WT myocytes was
55±2 minutes, whereas the ATPGD-1-Tg survived with
a mean lifetime of 72±6 minutes (Figure 4G through
4I). The ATPGD1-Tg cardiac myocytes were also resistant to acrolein-
induced hypercontracture. The
mean lifetime of WT cardiomyocytes superfused with
acrolein was 55±2 minutes, which was less than that
of ATPGD1-
Tg myocytes (72±5 minutes; Figure 4J
through 4L). Collectively, these results suggest that
high intracellular levels of carnosine protect against
the toxicity of a structurally diverse range of aldehydes
generated by lipid peroxidation.

ATPGD1 Overexpression Prevents
Ischemic Changes in [pH]i and High-
Energy Phosphate Content
Given that ATPGD1 overexpression enhanced myocardial histidyl dipeptide levels, which can buffer pH,2
we next tested whether it could also preserve change
in [pH]i during myocardial I/R. For this, we used 31P
NMR spectroscopy to measure the changes in myocardial ATP, phosphocreatine (PCr), and [pH]i during
I/R. Hearts isolated from the WT and ATPGD1-
Tg
mice were subjected to 20 minutes of perfusion, followed by 20 minutes of LFI (10% of baseline) and
50 minutes of reperfusion. Figure 5A and 5D shows
the representative 31P NMR spectra at baseline, LFI,
and reperfusion of the WT and ATPGD1-Tg isolated
hearts, respectively. From the left to right, the peaks
present inorganic phosphate; PCr; and γ, α, and β
phosphates of ATP; and the area under the curve of
respective resonances were used to calculate the
amount of each metabolite. The baseline spectra of
PCr was similar between the WT and ATPGD1-Tg
hearts, which was reduced to ~50% of baseline in
both the WT and ATPGD1-Tg hearts during LFI; however, the decrease was slightly less pronounced in
the ATPGD1-Tg hearts. During reperfusion, the PCr
recovery in the WT hearts was nearly 100%; however,
in the ATPGD1-Tg hearts, the PCr recovery exceeded
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Figure 5. ATPGD1 (carnosine synthase) overexpression enhances buffering capacity during ischemia reperfusion injury.
Representative 31P NMR spectra from wild-type (WT) (A) and ATPGD1-transgenic (Tg) (D) hearts during baseline, low-flow ischemia
(LFI), and reperfusion. Pi, PCr, γ, α, β denotes inorganic phosphate, phosphocreatine, and resonances of ATP, respectively. Changes
in PCr (B), ATP (C), Pi (E), and pH (F) during baseline, LFI, and reperfusion. Data are mean±SEM; n=6 mice in each group. *P<0.05 vs
WT, #P<0.05 vs WT baseline, and ^P<0.05 vs ATPGD-Tg baseline.
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the baseline levels and remained higher than in WT
hearts throughout the reperfusion (Figure 5B). Basal
ATP levels were similar between the WT and the
ATPGD1-Tg hearts, and LFI resulted in a 40% to 50%
decrease in ATP levels in the WT hearts, which did
not recover during reperfusion. In contrast, the ATP
levels in the ATPGD1-Tg hearts decreased to only
30% to 40% of the baseline during LFI and remained
higher than in the WT hearts (Figure 5C). The inorganic phosphate increased substantially in both the
WT and ATPGD1-Tg hearts during LFI and reached
preischemic levels during reperfusion in both groups
(Figure 5E). These results suggest that increasing the
abundance of carnosine in the heart prevents the
loss of high-energy phosphates during ischemia and
promotes their restoration during reperfusion.
At baseline, [pH]i was similar between the WT and
ATPGD1-
Tg hearts (7.13±0.04 versus 7.14±0.01),
but in WT hearts, [pH]i fell rapidly by 0.34±0.02 pH
units after 10 minutes and 0.45±0.02 pH units after
20 minutes of LFI. In contrast, there was less acidosis
in the ATPGD1-Tg hearts. In these hearts, the mean
fall of [pH]i was 0.23±0.02 units after 10 minutes and
0.32±0.03 units after 20 minutes of LFI. During the first
10 minutes of reperfusion, the [pH]i in the WT hearts
reached 6.92±0.01 and thus had recovered 0.21±0.01
pH units. However, in the ATPGD1-Tg hearts, the [pH]i
reached 7.03±0.01, suggesting a greater recovery
of [pH]i compared with the WT hearts. The rates of
[pH]i recovery during 20 to 50 minutes of reperfusion

was delayed in the WT hearts and did not reach preischemic levels, whereas the [pH]i in the ATPGD1-Tg
hearts after 30 to 40 minutes of reperfusion was similar to baseline (7.08±0.01 versus 7.13±0.01; Figure 5F).
Taken together, these results provide direct evidence
that ATPGD1 overexpression augments intracellular
buffering and mitigates acidosis during I/R.

Both Buffering and Aldehyde Quenching
Are Essential for Cardiac Protection by
Histidyl Dipeptides
Because ATPGD1 overexpression seems to protect against carbonyl stress and [pH]i imbalance,
we next examined which of these properties might
be essential for cardioprotection. To test the relative contribution of aldehyde quenching and buffering, we synthesized the natural carnosine analog
anserine, which is methylated at the Nπ residue of
histidine and has aldehyde-binding capacity similar
to carnosine (Figure S2).39 However, in comparison
with carnosine, anserine has a lower buffering capacity (pKa 7.15).40 In addition, we also synthesized
balenine, which is methylated at the Nτ residue of
histidine, and therefore has a higher buffering (pKa
6.93), yet lower aldehyde binding, capacity than
does carnosine.21,40 Thus, unlike carnosine, balenine does not protect cardiomyocytes against
aldehyde-induced hypercontracture.21 To determine
how the differential biochemical properties of these
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dipeptides influences I/R injury, we perfused isolated C57/BL6 mice hearts with either anserine or
balenine (1 mmol/L) and subjected these hearts to
I/R as previously. The results of these experiments
showed that neither balenine nor anserine was able
to improve the recovery of postischemic contractile
function (Figure 6A and 6B). The release of cardiac
enzymes (creatine kinase and lactate dehydrogenase) in balenine-
perfused and anserine-
perfused
hearts was similar in magnitude to their release in
untreated WT hearts (Figure 6C through 6F). From

these results, we infer that the loss of either the buffering capacity or aldehyde binding abolishes the
cardioprotective effects of histidyl dipeptides, and
therefore both of these properties are essential for
the cardioprotective effects of carnosine.

ATPGD1 Overexpression Preserves
Intermediary Metabolism During Ischemia
Extensive evidence suggests that elevated glucose
levels could be beneficial to improve recovery from I/R
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Figure 6. Histidyl dipeptide analogs balenine and anserine were unable to restore the contractile
function.
Changes in the developed pressure of C57BL/6 mice hearts perfused with (A) balenine and (B) anserine
followed by 30 minutes of ischemia and 45 minutes of reperfusion. Data are mean±SEM; n=4 mice
hearts in each group. *P<0.5 vs wild-type heart. Levels of creatine kinase (CK) (C and D) and lactate
dehydrogenase (LDH) (E and F) released in the perfusate collected at different intervals of reperfusion.
LVDP indicates left ventricular developed pressures.
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B

Figure 7. Anaerobic glycolysis is increased in carnosine synthase-t ransgenic (Tg) ischemic hearts.
A, Wild-t ype (WT) and ATPGD1-Tg isolated hearts were perfused for 10 minutes with 13C D-glucose in the Langendorff mode, followed
by 20 minutes of low flow ischemia. Levels of (A) 13C D-glucose and (B) 13C-lactate in perfusates collected at different time intervals.
Data are mean±SEM; n=5 mice in each group. *P<0.05 vs WT heart. ATPGD1 indicates carnosine synthase.

Downloaded from http://ahajournals.org by on January 10, 2021

injury.41–43 Our results so far suggested that ATPGD1
overexpression prevents intracellular acidification
during ischemia. Although it has been proposed that
carnosine promotes glycolysis by buffering pH,2 direct evidence for such a proglycolytic effect is lacking.
To examine whether ATPGD1 overexpression affects
glycolysis, we perfused isolated WT and ATPGD1-Tg
hearts with13C glucose for 10 minutes followed by
20 minutes of LFI. Perfusates from these hearts were
collected at different times and analyzed for13C glucose and13C lactate by liquid chromatography–mass
spectrometry. We found that the13C glucose levels
measured at different time points of LFI were similar
between the WT and ATPGD1-Tg hearts. However,13C
lactate formation during 1, 2, and 10 minutes of LFI
was higher in the perfusates of the ATPGD1-Tg rather
than the WT hearts (Figure 6B and 7A). Taken together, these results suggest that despite the similar levels of glucose uptake, ATPGD1 overexpression
increases glucose use under ischemic conditions,
presumably by increasing the rates of glycolysis by
buffering [pH]i.

DISCUSSION
The major findings of this study are that cardiac myocyte–restricted overexpression of ATPGD1 enhances
myocardial production of carnosine and thereby protects the heart from I/R injury. In addition, augmenting
myocardial carnosine levels by β-alanine or carnosine supplementation also imparts cardioprotection.
Our results show that ATPGD1 overexpression decreased the formation of protein-
aldehyde adducts
in the ischemic heart and diminished the toxicity of
lipid peroxidation products. We also found that the

overexpression of ATPGD1 attenuated I/R-
induced
changes in [pH]i and intermediary metabolism that accompany myocardial I/R. The protective effects of carnosine were not duplicated by the structurally related
histidyl dipeptides anserine and balenine, suggesting
that the multifunctional chemistry of carnosine is essential for cardioprotection. Taken together, these findings for the first time reveal a direct cardioprotective
role of ATPGD1 and uncover new aspects of cardioprotection against myocardial ischemic injury targeted by
ATPGD1-synthesized dipeptides. Given that ATPGD1
synthesizes multifaceted dipeptides, which are readily
hydrolyzed in human serum diminishing its bioavailability, these results suggest that modulating the endogenous production via ATPGD1 overexpression may be
a key strategy to prevent and attenuate myocardial I/R
injury and related pathological conditions in humans.
Carnosine, anserine, and balenine are evolutionarily
conserved dipeptides that are present in a high abundance in energetically active tissues such as the striated muscles and neurons.2 Among these dipeptides,
carnosine is widely present in the humans, whereas
anserine and balenine are mostly found at relatively
higher levels in birds and whales, respectively.40 In this
study, we found that the mouse heart contains 300 to
350 nmoles/g protein of carnosine and 75 to 80 nmoles/g protein of anserine, which are consistent with the
expected distribution of these peptides in mammalian
hearts. Nevertheless, despite their near ubiquitous
distribution, the physiological role of these peptides
is understudied, and it is unclear what specific function they perform in different tissues. Most previous
studies on histidyl dipeptides has focused on their
potential ability to increase exercise capacity, and β-
alanine is frequently ingested by professional athletes
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as a performance-enhancing supplement. The skeletal muscle levels of carnosine are increased by high-
intensity exercise, suggesting that it plays an important
role in skeletal muscle physiology.36 Although the specific mechanisms by which carnosine increases exercise capacity remain unknown. It is widely believed that
it can enhance exercise performance by buffering [pH]i
and thereby preserve glycolysis during hypoxia36,44,45;
however, direct evidence regarding the proglycolytic
effects is lacking.
In addition to buffering pH, carnosine can also react
with a variety of electrophiles, such as the reactive aldehydes generated by lipid peroxidation. Indeed, in our
previous work we found that carnosine reacts directly
with HNE and acrolein and that the resultant conjugates are metabolized and excreted in mouse and
human urine.27 Therefore, carnosine may be an endogenous antioxidant that removes reactive aldehyde
species, acting in parallel to glutathione-linked detoxification. This notion is supported by our recent observation that an increase in carnosine levels attributed to
β-alanine supplementation results in increased scavenging of lipid peroxidation products in human skeletal muscle, generated during high-intensity exercise.36
Carnosine treatment has also been reported to protect
the brain from ischemic damage,29 and topical administration of carnosine accelerates wound healing in db/
db mice.46 Carnosine perfusion in isolated hearts has
also been shown to marginally improve functional recovery of isolated ischemic rat and mice hearts.27,28,47
Nonetheless, the mechanisms underlying the cardioprotective effects of carnosine remain unknown, and
it is unclear whether carnosine protects by targeting
extracellular sites or intracellular pathology and which
cell types in the heart are targeted. Therefore, we
generated ATPGD1-
Tg mice to selectively increase
carnosine levels within cardiomyocytes, and we undertook a comprehensive evaluation of the mechanisms
of carnosine-mediated cardioprotection.
We found that the cardiospecific overexpression
of ATPGD1 reduced the infarct size both in vivo and
ex vivo and that cardiac myocytes overexpressing
ATPDGD1 were resistant to hypoxia reoxygenation injury. Although cardiospecific ATPGD1 overexpression
enhanced the myocardial levels of histidyl dipeptides
40-to 50-fold and mice fed with β-alanine and carnosine enhanced the myocardial carnosine levels 4-to
7-fold, both treatments had similar infarct-sparing effects, suggesting that physiological dosing of β-alanine
and carnosine could be cardioprotective. Together
these observations provide unequivocal evidence that
carnosine protects the heart by targeting sites and
events within cardiac myocytes, without directly affecting extracellular events, neurohormonal changes,
or even inflammatory responses that accompany myocardial I/R.

Carnosine Protects From Ischemia Reperfusion

Previous work has shown that myocardial ischemia
is associated with acidification and a decrease in ATP
levels attributed to the progressive failure of glucose
and fatty acid metabolism. Myocardial ischemia also
creates conditions that promote ROS generation,
which exacerbates tissue injury and induces cell death.
However, the relationship between acidification and
loss of ATP is unclear, and the contribution of these
changes to the ROS generation has not been clarified.
Moreover, it is unclear to which extent ROS themselves
or the secondary products they generate mediate tissue injury. Although free radicals and ROS are highly
reactive, they are short lived and therefore much of
their injury has been attributed to their secondary, more
stable, products, such as the aldehydes generated by
lipid peroxidation.48,49 Several studies have shown that
lipid peroxidation–derived aldehydes accumulate in
cardiac tissue within 5 to 10 minutes of ischemia and
that these aldehydes propagate the I/R injury.16,22,50 Of
the several reactive aldehydes generated during I/R,
HNE and acrolein are the most potent and toxic species that promote ischemic injury.51–53 Given the extensive evidence linking reactive aldehydes to tissue
injury, we investigated whether increasing myocyte levels of carnosine protects the heart by detoxifying lipid
peroxidation products. We found that ATPGD1 overexpression decreased the accumulation of protein-HNE
and protein-acrolein adducts in the heart and that myocytes isolated from the ATPGD1-Tg heart were resistant to HNE and acrolein-induced hypercontracture.
When taken together, these observations support the
notion that the cardioprotective effects of high carnosine levels may be related to a greater antioxidant
capacity of myocytes, specifically their greater ability to
detoxify the toxic products of lipid peroxidation.
In addition to preventing oxidative injury, carnosine
could also protect the heart by buffering changes in
[pH]i. Because of its histidyl group, carnosine is an efficient buffer with a pKa value near [pH]i.40 Previous
studies with racehorses and greyhound dogs as well
as elite human sprinters have shown that high levels of
histidyl dipeptides can increase the intracellular buffering capacity of skeletal muscle.54,55 Moreover, it has
been recently suggested that the buffering potential of
the heart, augmented by exercise, might be associated
with an increase in the cardiac pool of histidyl dipeptides.56,57 Changes in [pH]i are an important aspect
of I/R injury. Extensive data have shown that acidification during I/R promotes cardiac injury by affecting
cardiac metabolism and mechanics.58–60 Because
carnosine has been shown to act as a mobile buffer
that regulates the Ca2+ and H+ signaling in isolated
cardiac myocytes,61 it seems that intracellular buffering may be important aspect of its cardioprotective
properties. Indeed, we found that although ATPGD1
overexpression did not affect basal [pH]i, it prevented
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the steep fall in pH and decreased the perpetuation of
acidotic pH during reperfusion. These results showing
that ATPGD1 overexpression diminishes the decline in
[pH]i provides direct evidence that [pH]i buffering by
histidyl dipeptides may be an essential feature of the
cardioprotective effects of carnosine. Nevertheless,
pH buffering does not seem to be the sole mechanism
of protection because perfusion with balenine, which
is as efficient a buffer as carnosine, did not ameliorate
I/R injury, suggesting that simply buffering [pH]i during
I/R is not sufficient for limiting I/R and that properties of
carnosine, other than buffering [pH]i, may be pertinent
to its cardioprotective effects. Nonetheless, the lack of
protection by anserine, which has a lower buffering capacity than carnosine, suggests that pH buffering by
carnosine is important. Because anserine has a lower
buffering capacity, we suggest that both aldehyde
quenching and buffering intracellular pH are important components of carnosine-
mediated protection.
Therefore, in comparison with previous interventions
with buffers and antioxidants, carnosine has a more
superior protective profile. Based on this evidence, it
appears that buffering and aldehyde quenching properties of carnosine, optimized by natural selection, may
be ideally suited for the protection of ischemic tissue.
This property of carnosine seems to be in contrast to
anserine and balenine, which are mostly abundant
in avian and whale hearts,40 suggesting that greater
abundance of carnosine may be acquired by land
mammals to optimize both the buffering and aldehyde-
quenching properties of histidyl dipeptides.
Our findings further suggest that the mechanism linking the cardioprotective effects of carnosine may relate to
the prevention of acidification and quenching of reactive
aldehydes generated during I/R injury. These changes
are likely to prevent metabolic derangements in ischemic tissue. Indeed, previous work has shown that interventions that promote glucose supply and use protect
the heart during ischemia and improve recovery during
reperfusion.43,62–64 Clinical studies with glucose-insulin-
potassium therapy, which augments glucose metabolism during acute myocardial ischemia, improves the
outcome in patients receiving thrombolytic therapy.65,66
In addition, the protective effects of buffering [pH]i may
also be related to the preservation of energy metabolism. For instance, it has been reported that during ischemia, delaying [pH]i decline by proton-buffering agents
preserves glycolysis and prevents myocardial injury.67,68
Our experiments with ATPGD1 hearts provide a direct
link between the two phenomena. We found that although glucose uptake in the WT and ATPGD1-Tg mice
hearts was similar, lactate formation was increased,
suggesting that increasing the buffering capacity during
ischemia facilitates anaerobic glycolysis. That ATPGD1
hearts also showed less severe depletion of high-energy
phosphates further reinforces the view that myocardial
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energetics could be preserved during ischemia by buffering [pH]i. Whether the salutary effects of ATPGD1
expression on glycolysis are attributed to buffering, aldehyde quenching, or direct effects on metabolic pathways requires further investigation. Nevertheless, our
current data provide strong evidence that carnosine prevents oxidative stress, acidification, and metabolic derangements that are key features of myocardial I/R injury
and therefore have high clinical relevance. Because carnosine is an endogenous dipeptide and its myocardial
levels could be modulated by exogenous supplementation or by modulation of the endogenous production, it
could be used therapeutically to promote recovery from
myocardial injury or prophylactically to prevent myocardial injury in susceptible individuals.
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Data S1.

SUPPLEMENTAL MATERIALS AND METHODS

Enhance histidyl dipeptide levels within the cardiac tissue

-Alanine and carnosine feeding. To enhance histidyl dipeptide pool within cardiac tissue, we treated WT
C57BL/6 mice (12-14 week) with -alanine (20 g/L) or carnosine (10 g/L) in drinking water or water alone for
seven days. Heart and skeletal muscle from the treated and untreated mice were collected and analyzed for
different histidyl dipeptides levels using LC/MS.
Generation of cardio specific carnosine synthase (ATPGD1) transgenic mice. To enhance endogenous
production of histidyl dipeptides within cardiac tissue, we generated cardio specific ATPGD1 transgenic (Tg)
mice. Full protein-coding sequence of the mouse (m) ATPGD1 cDNA (2.84 kb a kind gift from Dr. Emile Van
Schaftingen, Ludwig Institute for Cancer Research, Universite Catholique de Louvain, Belgium) was cloned
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under the control of mouse alpha-myosin heavy chain promoter (-MHC; 5.5 kb), 0.6 Kb HGH (human growth
hormone) poly A was ligated at the 3’ end of the minigene construct. Nucleotide sequencing and comparisons
with published sequences verified the construct as mATPGD1 cDNA. The resultant transgene (9.04 Kb)
composed of -MHC promoter, the entire protein-coding region of ATPGD1 and HGH polyadenylation signal
sequence. The transgene construct was linearized, purified, and microinjected into the pronuclei of fertilized
ova to generate -MHC-ATPGD1-Tg mice at the University of Cincinnati, Cincinnati, OH Transgenic Core. Four
transgenic founders with the varying copy number of the transgene were generated on the C57Bl/6 background.
Founder mice were identified by genomic PCR using the following primers: Forward-5’- AGT CCT GGT GGG
AGA GCC ATA -3’ and Reverse 5’ – GCC AAG CAG GGG ACA GGC AAA -3’ corresponding to -MHC 5’UTR
and the ATPGD1 coding region, respectively. Two transgenic (TG) lines were established and distinguished
from their non-transgenic wild type littermates (WT) cohorts by PCR.

Myocardial ischemia and reperfusion (I/R) injury in-vivo and assessment of area at risk and infarct size.
The I/R injury was produced by subjecting mice to a 30 min of coronary occlusion followed by 24 h of reperfusion
as described previously69-71. Briefly, the mice (10-14 weeks of age) were anesthetized with pentobarbital
sodium (50mg/kg, i.p) intubated and ventilated at room air supplemented with oxygen. The body temperature
was monitored with a rectal probe and maintained at 370.2C with a heating pad. To replace blood loss, blood
from a donor mouse was given intravenously. The chest was opened through a midline sternotomy, and a
nontraumatic balloon occluder was applied on the left anterior descending coronary artery 2-3 mm from the tip
of left auricle. Successful performance of the surgery was verified by noting the development of a pale color in
the distal myocardium on inflation of the balloon and return of a bright red color due to hyperemia after deflation
and by observing the ST-segment elevation and widening of the QRS complex on the ECG during ischemia
and their resolution after reperfusion. Following the coronary occlusion/reperfusion, the chest was closed in
layers, and the mice were allowed to recover under close monitoring. Heart was excised and perfused with
Krebs-Henseleit (KH) solution through an aortic cannula. To determine the area of infarcted myocardium from
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the viable myocardium, the heart was perfused with 1% triphenyl tetrazolium chloride in phosphate buffer. To
delineate the area of occlusion, the coronary artery was tied at the site of previous occlusion, and the aortic
root was perfused with 10% Pthalo blue dye. The region of risk was identified by the absence of blue dye,
whereas the rest of left ventricle was stained dark blue. The left ventricle was cut into transverse slices, which
were fixed in 10% neutral buffered formaldehyde, weighed, and photographed under a microscope. The
corresponding areas were measured by computerized planimetry and from these measurements; the infarct
size was calculated as the percentage of region at risk.
In the second set of experiments, coronary ligation was performed, to analyze the formation of aldehyde protein
adduct during ischemic injury. Hearts from the WT and ATPGD1-Tg mice were collected following 40 min of
ligation. The ischemic zone of ligated mice and the anterior zone of sham-operated mice were clamp frozen
and analyzed by Western blotting.
Langendorff perfusion

Global ischemia-reperfusion (I/R) ex vivo. To exclude the neurohormonal effects associated with in-vivo
model of I/R, we performed I/R in a Langendorff mode as described previously27. Mice were anesthetized
(sodium pentobarbital, 60mg/kg body weight, heparin, 10 units/g body weight), the thorax of mice was opened
and the hearts were removed, placed immediately in the ice-cold KH buffer; mM 118 NaCl, 4.7 KCl, MgCl2,
CaCl2, KH2PO4, NaHCO3 and 11 glucose. The buffer was heated at 37C and continuously gassed (95% O2,
5%CO2). Hearts from the WT and ATPGD1-Tg, mice were continuously perfused at a constant pressure of 80
mmHg in the Langendorff mode and after 20-30 min of perfusion, the isolated hearts were subjected to 30 min
of ischemia followed by 45 min of reperfusion. Functional recovery of the hearts was measured by placing a
food grade plastic wrap, fluid-filled balloon to a pressure of 5-8 mm Hg. Left ventricular pressure was recorded
using an APT300 pressure transducer (Harvard Apparatus, Holliston, MA) connected to a ML221 bridge
amplifier, a Power lab 16/30 A/D board, and a PC running Lab Chart Pro v7 (AD Instruments, Colorado Springs,
CO). Perfusion flow rate was monitored using a 1PXN inline probe and TS410 flowmeter (transonic Systems
Inc., Ithaca, NY) and was typically between 1.5 and 2 mL/min. Left ventricular developed pressure was derived
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from the pressure trace as the difference between systolic and diastolic pressures. Perfusates were collected
on ice and the levels of creatinine kinase (CK) and lactate dehydrogenase (LDH) were measured using kits
purchased from Thermo-Electron.
In a second line of experiments, we tested which dipeptide analogue could lead to recovery of function following
ischemia. For these experiments, wild type (WT) C57/Bl6 mice (12-14 weeks old) were perfused with either
balenine and anserine (1mM), followed by 30 min of ischemia and 45 min of reperfusion and the recovery of
cardiac function was monitored in a Langendorff mode as described above.
Low flow ischemia and 13C D-glucose perfusion: To determine whether ATPGD1 overexpression influences
the glycolytic fluxes during ischemic injury, isolated WT and ATPGD1-Tg mice hearts were perfused in the
Langendorff mode for 10 min in a KH buffer; mM 118 NaCl, 4.7 KCl, MgCl2, CaCl2, KH2PO4, NaHCO3 and 11
13

C-D-glucose followed by 15 min of low flow ischemia (LFI, 10% of baseline). The effluent was collected at

regular intervals and analyzed for 13C D-glucose and 13C lactate.

31

P Nuclear Magnetic Resonance Spectroscopy: Hearts isolated from the WT and ATPGD1-Tg mice were

perfused in a Langendorff mode with KH buffer at constant coronary pressure of 75 mmHg at 37C for 10 min
followed by 20 min LFI (10% of baseline) and 50 min reperfusion.

31

P-NMR spectra were collected continuously

and simultaneously during measurement of isovolumic contractile performance using 31P-NMR spectroscopy.
72

Isolated perfused hearts and an external standard containing 4.51 mol of phenylphosphonic acid (PPA) in

a small sealed plastic tube were placed in a 10-mm glass NMR sample tube and inserted into a 10 mm Varian
broad band probe situated in an 89-mm bore 9.4-T superconducting magnet. To improve homogeneity of the
NMR-sensitive volume, the perfusate level was adjusted so that the heart was submerged in buffer.

31

P-NMR

spectra were obtained using 60 pulses and a recycle time of 2.4 S, 6,000-Hz sweep width and 2 K data points
at 161.94 MHz using a Varian Inova spectrometer (Varian Inc., Palo Alto, CA). Single spectra were collected
during 10 min periods and consisted of data averaged from 256 free induction decays. Spectra were processed
using 20-Hz exponential multiplication and zero and first-order phase corrections. The resonance areas of
phosphocreatine (PCr), ATP, inorganic phosphate (Pi) and the chemical shifts of Pi were quantified using
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Bayesian Analysis Software (G.L. Bretthorst Washington University, St. Louis, MO)

73

.

By comparing the

amplitude under the peaks from fully relaxed (recycle time 15 sec) and those of partially saturated (recycle time
2.4 sec) spectra, the correction factors for saturation were calculated for ATP (1.041), PCr (1.285), Pi (1.157)
and PPA (1.283).

Cell culture studies
Isolation of adult cardiomyocytes. Cardiac myocytes from the WT and ATPGD1-Tg mice hearts (age 12-16
weeks) were isolated using Langendorff perfusion as described previously.74 21 Isolated hearts from these mice
were rinsed in physiological saline and perfused with oxygenated (95% O2- 5%CO2), Ca2+- free modified Tyrode
bicarbonate buffer (buffer A mM: NaCl 126, KCL 4.4, MgCl2 1.0, NaHCO3 18, glucose 11, HEPES 4, 2,3
butanedione monoxime 10, taurine 30, pH 7.35) at 37C for 5 min. The extracellular matrix was digested by
buffer containing buffer A with Liberase Blendzyme type I 0.25 mg/mL, 1mg/mL albumin, 0.015 mg/mL DNase,
0.015 mg/mL proteinase in the 50 mL of recirculating digestion buffer (buffer A with 25 M CaCl2) for 12-15

min. Hearts were separated in mincing buffer (10 mL digestion buffer with 9 mg/mL albumin and Liberase) and
cells were allowed to settle. CaCl2 was reintroduced in a graded fashion at 5- min intervals (five total steps) to
sequentially increase the Ca2+ concentration to 500 M.
Hypoxia reoxygenation of adult cardiomyocytes. Cardiomyocytes isolated from WT and ATPGD1-TG mice
hearts were subjected to 2-3 h of hypoxia using a controlled hypoxic chamber (Billups-Rothenberg Modulao,
Incubator Chamber) maintained at 37C. Freshly isolated cells were maintained in serum free/ glucose free
HEPES-buffered medium (mM: NaCl 113, KCL 4.7, HEPES 10, MgSO4 1.2, taurine 30, CaCl2 1, pH 6.2 ) at
37C. Cells were allowed to settle down, supernatant was removed and replaced with hypoxia buffer (glucose
free/serum free HEPES buffered medium that was bubbled with nitrogen (N2). The dishes were filled with 1 mL
of hypoxia buffer and incubated in a humidified hypoxic chamber containing: 1% O2, 5% CO2 and 94% N2 at
37C. Following hypoxia, the cells were re oxygenated with 1 mL of HEPES buffered medium supplemented
with serum (10%) and glucose (11 mM) bubbled with O2 and placed under normoxic conditions. For control
conditions, freshly isolated cells were washed twice with a HEPES-buffered medium supplemented with serum
Downloaded from http://ahajournals.org by on January 10, 2021

(5%) and glucose (5.5 mM) and placed under normoxic conditions. Reoxygenation was mimicked by adding 1
mL of the medium. The supernatant was collected and analyzed for LDH release.
Superfusion of isolated cardiomyocytes with HNE and acrolein. To examine whether the increase in
endogenous production of histidyl dipeptides protects against aldehyde induced hypercontracture, adult
cardiomyocytes from the WT and ATPGD1-Tg mice hearts were superfused with 50-60 M HNE or 5 M
acrolein for 60 min as described previously.21 Digital images of approx. 100 cardiomyocyte/field were acquired
at 5 min interval to quantify the number of hypercontracted and non-hypercontracted cells following aldehyde
treatment.
Western blot analysis
The anterior zone of sham operated and ischemic zone of the ligated mice hearts were homogenized and
separated by SDS-PAGE. Tissues were homogenized in RIPA buffer (20mM Tris-HCl pH7.5, 150 mM NaCl,
1mM EDTA, 1mM EDTA, 1mMEGTA, 1% NP-40) and separated by SDS-PAGE. Immunoblots were developed

using anti-acrolein (0.25 g/ mL, Novus Biological), anti-HNE (0.5 g/mL, Abcam) and anti- ATPGD1 (0.25 g/
mL COSMO Bio Company) antibodies. Western blots were developed using ECL Plus reagent and detected
with a Typhoon 9400 Variable mode imager. Band intensity was quantified by using an Image Quant TL
software and bands were normalized to amido black or tubulin.
LC/MS studies
Measurement of histidyl dipeptides by LC/MS. Histidyl dipeptides in the heart and skeletal muscle were
measured by LC/MS as described previously36. Briefly the isolated tissues from mice were homogenized in
extraction buffer containing 10 mM HCl and 200 M tyrosine-histidine as an internal standard (IS).
Homogenates were sonicated on ice for 10 s, centrifuged at 16,000  g for 10 min at 4C. Supernatants were
injected into TQ-S micro mass spectrometer in positive mode, the samples were diluted in 75% acetonitrile/25%
water. The dipeptides were separated and identified by using Water ACQUITY UPLV H-Class system coupled
with a Xevo TQ-S micro triple quadrupole mass spectrometer (MS). The analytes were separated by a Waters
Acquity BEH HILIC column (1.7m, 2.1 50) equipped with an in-line frit filter unit. The analytes were eluted by
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using a binary solvent system consisting of 10 mM ammonium formate, 0.125% formic acid in 50%
acetonitrile/50% water for mobile phase A and 10 mM ammonium formate 0.125% formic acid in 95%
acetonitrile/5% water for mobile phase B at a flow rated of 0.55 ml/min. Initial conditions were 0.1:99.9 A/B
ramping to 99.9:0.1 A/B over 5 min then quickly ramping to 0.1:99.9 A/B over 0.5 min. This initial composition
was held from 5.5 to 8 min to equilibrate the column for the next injection. Dipeptides were quantified using the
LC/MS calibration curve of relative area of carnosine and anserine to internal standard tyrosine-histidine and
expressed as mole/mg wet wt. or mole/mg protein. For carnosine m/z 227→110, anserine m/z 241→110, and
tyrosine-histidine m/z 319→110, Da MRM transitions were followed.
13

C glucose and 13C lactate analysis.
Perfusates collected from the WT and ATPGD1-Tg hearts perfused with

13

C glucose and subjected to low

flow ischemia as described above were dried and dissolved in 200 µL 20% acetonitrile and vigorously vortex-

mixed for 3 min. After centrifugation at 14,000 rpm, 4 oC for 20 min, the supernatant was collected for 2DLCMS/MS analysis.
All samples were analyzed on a Thermo Q Exactive HF Hybrid Quadrupole-Orbitrap Mass Spectrometer
coupled with a Thermo DIONEX UltiMate 3000 HPLC system (Thermo Fisher Scientific, Waltham, MA, USA).
The UltiMate 3000 HPLC system was equipped with a reverse phase chromatography (RPC) column and a
hydrophilic interaction chromatography (HILIC) column. The RPC column was an ACQUITY UPLC HSS T3
column (150 × 2.1 mm i.d., 1.8 µm) purchased from Waters (Milford, MA, USA). The HILIC column was a
SeQuant® ZIC®-cHILIC HPLC column (150 × 2.1 mm i.d., 3 µm) purchased from Phenomenex (Torrance, CA,
USA). The two columns were configured in parallel 2DLC mode 75. For 2DLC separation, H2O with 0.1% formic
acid was used as the mobile phase A for RPC and 10 mM ammonium acetate (pH 3.25) was used as the
mobile phase A for HILIC. Acetonitrile with 0.1% formic acid was used as mobile phase B for both RPC and
HILIC. The RPC gradient was as follows: 0 min, 5% B, hold for 5.0 min; 5.0 min to 6.1 min, 5% B to 15% B; 6.1
min to 10.0 min, 15% B to 60% B, hold for 2.0 min; 12.0 min to 14.0 min, 60% B to 100% B, hold for 13.0 min;
Downloaded from http://ahajournals.org by on January 10, 2021

27.0 min to 27.1 min, 100% B to 5% B, hold for 12.9 min. The gradient for HILIC separation was: 0 to 5.0 min,
95% B to 35% B, hold for 1.0 min; 6.0 min to 6.1 min, 35% B to 5% B, hold for 16.9 min; 23.0 min to 23.1 min,
5% B to 95% B, hold for 16.9 min. The flow rate was 0.4 mL/min for RPC and 0.3 mL/min for HILIC. The column
temperature was 40 °C for both columns. The injection volume was 2 µL for each column.
To avoid systemic bias, the samples were analyzed by 2DLC-MS in a random order. All samples were first
analyzed by 2DLC-MS positive mode followed by 2DLC-MS negative mode, to obtain the full MS data of each
metabolite. For quality control purpose, a group-based pooled sample was prepared by mixing a small portion
of the supernatant from all unlabeled samples in one group. One pooled sample was analyzed by 2DLC-MS
after injection of every 5 biological samples. All pooled samples were analyzed by 2DLC-MS/MS in positive
and negative mode respectively to acquire MS/MS spectra of each metabolite at three collision energies (20
eV, 40 eV and 60 eV).
MetSign software was used for spectrum deconvolution, metabolite identification, cross-sample peak list
alignment, normalization, and statistical analysis

76-78

. To identify metabolites, the 2DLC-MS/MS data of the

pooled samples were first matched to an in-house MS/MS database that contains the parent ion m/z, MS/MS
spectra, and retention time of 205 metabolite standards. The thresholds used for metabolite identification were
MS/MS spectral similarity ≥ 0.4, retention time difference ≤ 0.15 min, and m/z difference ≤ 4 ppm. The 2DLCMS/MS data without a match in the in-house database were then analyzed using Compound Discoverer
software (v2.0, Thermo Fisher Scientific, Inc., Germany), where the threshold of MS/MS spectrum similarity
score was set as ≥ 40 with a maximum score of 100. The remaining peaks that did not have a match were then
matched to the metabolites in -house MS/MS database using the parent ion m/z and retention time to identify
metabolites that do not have MS/MS spectra. The thresholds for assignment were parent ion m/z ≤ 4 ppm and
retention time difference ≤ 0.15 min.
Synthesis of histidyl dipeptide analogues anserine and balenine

(a) Balenine was synthesized as mentioned previously.21
(b) Anserine synthesis

(S)-Methyl 3-(1H-imidazol-5-yl)-2-(2,2,2-trifluoroacetamido) propanoate (3):
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To L-histidine dihydrochloride (5.00 g, 20.65 mmol) in methanol (100 mL), we added ethyl 2,2,2trifluoroacetate (2.70 mL, 22.72 mmol) and triethyl amine (1.52 mL, 82.6 mmol) and the reaction
mixture was stirred for 5 h at room temperature (RT). The solvent was evaporated to dryness and the
obtained solid was purified by silica gel chromatography to get the desired product, (S)-methyl 3-(1Himidazol-5-yl)-2-(2,2,2-trifluoroacetamido) propanoate, (3, 4.10 g, 75% yield) as an off-white solid
compound.
1H

NMR (D2O, 400 MHz): δ 7.60 (s, 1H), 6.87 (s, 1H), 4.76 – 4.67 (m, 1H), 3.66 (s, 3H), 3.17 – 2.96

(m, 2H) ppm.
(S)-Methyl 2-(2,2,2-trifluoroacetamido)-3-(1-trityl-1H-imidazol-4-yl) propanoate (4):

Trityl chloride (5.60 g, 20.36 mmol) and triethyl amine (8.53 mL, 61.53 mmol) were dissolved in
anhydrous

benzene

(100mL)

and

(S)-methyl3-(1H-imidazol-5-yl)-2-(2,2,2-trifluoroacetamido)

propanoate (3, 5.40 g, 20.36 mmol) was added. The resulting reaction mixture was refluxed for 1 h
and the solvent was evaporated. Obtained semi pure compound was purified with silica gel column
using dichloromethane and methanol was used as eluents to get (S)-methyl 2-(2,2,2trifluoroacetamido)-3-(1-trityl-1H-imidazol-4-yl) propanoate (4, 5.80 g, 55% yield) as an off-white solid
compound.
1H

NMR (CDCl3, 400 MHz): δ 8.89 – 8.87 (d, 1H), 7.40 (s, 1H), 7.37 – 7.30 (m, 9H), 7.13 – 7.07 (m,

6H), 6.57 (s, 1H), 4.85 – 4.79 (m, 1H), 3.63 (s, 3H), 3.16 – 3.11 (m, 1H), 3.06 – 3.00 (m, 1H) ppm.
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(S)-4-(3-Methoxy-3-oxo-2-(2,2,2-trifluoroacetamido)

propyl)-3-methyl-1-trityl-1H-imidazol-3-ium

iodide (5):

(S)-Methyl 2-(2,2,2-trifluoroacetamido)-3-(1-trityl-1H-imidazol-4-yl) propanoate (3.50 g, 6.90 mmol)
was dissolved in anhydrous acetonitrile (100 mL) and methyl iodide (0.86 mL, 13.80 mmol) was
added. The resulting reaction mixture was refluxed for 1 h and the solvent was evaporated. Obtained
crude was purified with silica gel column using dichloromethane and methanol as eluents to get (S)4-(3-methoxy-3-oxo-2-(2,2,2-trifluoroacetamido) propyl)-3-methyl-1-trityl-1H-imidazol-3-ium iodide (5,
4.0 g, 89% yield) as a yellow solid compound.

1H

NMR (CDCl3, 400 MHz): δ 8.26 – 8.25 (d, 1H), 7.48 – 7.38 (m, 7H), 7.35 – 7.20 (m, 10H), 4.86 -

4.79 (m, 1H), 4.03 (s, 3H), 3.78 (s, 3H), 3.56 – 3.41 (m, 2H) ppm.
(S)-1-Carboxy-2-(1-methyl-1H-imidazol-5-yl)ethanaminium chloride (6):

In a round bottom flask, we added (S)-4-(3-methoxy-3-oxo-2-(2,2,2-trifluoroacetamido) propyl)-3methyl-1-trityl-1H-imidazol-3-ium iodide (5, 4.0 g, 6.16 mmol) and 4N HCl (100 mL). The reaction
mixture was refluxed for 6 h, and evaporated to dryness, and the solid obtained was washed with
hexanes and dried to get (S)-1-carboxy-2-(1-methyl-1H-imidazol-5-yl) ethanaminium chloride, (6, 1.10
g, 87% yield) as a yellow solid compound.
1H

NMR (D2O, 400 MHz): δ 8.62 (s, 1H), 7.36 (s, 1H), 4.26 – 4.19 (m, 1H), 3.78 (s, 3H), 3.41 – 3.25

(m, 2H) ppm.
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(S)-Methyl 2-amino-3-(1-methyl-1H-imidazol-4-yl) propanoate hydrochloride (7):

In 300 mL of methanolic hydrochloric acid was added (S)-2-amino-3-(1-methyl-1H-imidazol-5-yl)
propanoic acid hydrochloride (2.60 g, 12.64 mmol) at room temperature. The reaction mixture was
then refluxed for 48 h, and evaporated to dryness to get (S)-methyl 2-amino-3-(1-methyl-1H-imidazol4-yl) propanoate hydrochloride, (7, 2.5 g, 90% yield) as a white solid. (Note: Methanolic-HCl was made
by purging HCl gas into required methanol for 5 min.)
1H

NMR (D2O, 400 MHz): δ 8.62 (s, 1H), 7.39 (s, 1H), 4.45 – 4.19 (m, 1H), 3.78 (s, 3H), 3.76 (s, 3H),

3.47 - 3.26 (m, 2H) ppm.

(S)-Methyl
2-(3-(tert-butoxycarbonylamino)
propanoate (8):

propanamido)-3-(1-methyl-1H-imidazol-5-yl)

Added sequentially to a reaction flask under nitrogen were (S)-methyl 2-amino-3-(1-methyl-1Himidazol-5-yl)propanoate hydrochloride (7, 2.0 g, 9.10 mmol), boc-b-alanine (1.89 g, 10.02 mmol),
EDC (N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide) (1.92 g, 10.02 mmol) followed by DCM (100
mL) and then N-methylmorpholine (4.00 mL, 36.4 mmol via syringe). The contents were stirred at
room temperature under nitrogen and the solids gradually dissolved. The contents were stirred at
room temperature for 24 h, and then slowly diluted into iced water and extracted with DCM. The
organic phase was dried evaporated and chromatographed using dichloromethane and methanol as
eluents to get (S)-methyl 2-(3-(tert-butoxycarbonylamino) propanamido)-3-(1-methyl-1H-imidazol-5Downloaded from http://ahajournals.org by on January 10, 2021

yl) propanoate (8, 2.0 g, 62% yield) as an off-white solid compound.
1H

NMR (CDCl3, 400 MHz): δ 7.37 (s, 1H), 6.75 (s, 1H), 6.66 – 6.50 (m, 1H), 5.15 – 5.08 (m, 1H), 4.82

– 4.77 (m, 1H), 3.74 (s, 3H), 3.57 (s, 3H), 3.45 – 3.30 (m, 3H), 3.16 – 3.02 (m, 1H), 2.50 – 2.35 (m,
2H), 1.42 (s, 9H) ppm.

L-Anserine (9):

To

(S)-methyl

2-(3-(tert-butoxycarbonylamino)

propanamido)-3-(1-methyl-1H-imidazol-4-yl)

propanoate (8, 2.2 g, 6.2 mmol) was added 2N NaOH (18.6 mL) in THF (50 mL) and methanol (50
mL) and the reaction was stirred for the 24 h at RT. Solvent was evaporated and the reaction mixture

was neutralized by 1N HCl to pH 3. It was further stirred and neutralized by aqueous saturated sodium
bicarbonate solution. All the water was evaporated to dryness and the obtained solid was triturated
with DCM and dried again. The obtained solid was dissolved in hot ethanol and passed through the
celite plug, twice. Filtrate was evaporated and dried under high vacuum to get the L-anserine (9, 1.30
g, 87% yield) as a white solid compound.
1H

NMR (D2O, 400 MHz): δ 8.61 (s, 1H), 7.27 (s, 1H), 4.54 – 4.50 (m, 1H), 3.86 (s, 3H), 3.31 – 3.19

(m, 3H), 3.14 – 3.07 (m, 1H), 2.80 – 2.64 (m, 2H) ppm;

13C

NMR (D2O, 100 MHz) δ 176.3, 171.7,

135.1, 131.3, 117.5, 53.2, 35.2, 33.1, 31.9, 25.8.
Echocardiographic analysis of cardiac function
Transthoracic echocardiography of the left ventricle was performed using a Vevo 770
echocardiography system as described previously.
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Briefly the body temperature of the mice was

maintained (36.5 -37.5C) using a rectal thermometer interfaced with a servo-controlled heat lamp.
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Mice were anesthetized with 2% isoflurane, maintained under anesthesia with 1.5% isoflurane. The
chest was shaved and the mouse was placed chest up on an examination board interfaced with the
Vevo 770. The 707-B (30 MHZ) scan head was used to obtain 2D images of the parasternal long axis.
M-modes were taken from the same anatomical position. The probe was then rotated to acquire a
short axis view of the heart. Stroke volume (SV) was calculated as: Diastolic Volume-Systolic Volume.
Ejection fraction was calculated as (SV/Diastolic Volume) *100%. Cardiac output was determined by:
SV*HR. All images were acquired with the Vevo 770’s rail system to maintain probe placement and
allow for precise adjustments of position. Left ventricular diameters during diastole (LVIDd) and left
ventricular diameter during systole (LVIDs) and heart rate (HR) were determined from long axis Mmodes. Left ventricular fractional shortening (%FS) was calculated as ((LVIDd-LVIDs)/LVIDd) *100%.

Figure S1. Histidyl dipeptide levels are enhanced in the carnosine synthase (ATPGD1-Tg)
heart.
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Levels of carnosine in the (A) heart and (C) gastrocnemius skeletal muscle of WT and ATPGD1Tg mice. Levels of anserine in the (B) heart and (D) skeletal muscle of WT and ATPGD1-Tg mice. Levels
of anserine in the hearts of (E) -alanine and (F) carnosine fed mice. Data is presented as meanSEM, n=4
mice in each group, *p<0.05 vs WT heart.

Figure S2. Synthesis of anserine.
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Table S1. Echocardiographic parameters of the wild type and ATPGD1-Tg hearts, age 12-14-week, n=7
in each group.

LVIDd(mm)
LVIDs(mm)
EF(%)
Heart rate
FS

Data are presented as S.D. in each group.

Baseline
WT
ATPGD1-Tg
3.95±0.05
3.98±0.07
2.27±0.07
2.48±0.09
63±1
60±1
580±5
540±5
41±1
38±2
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